Nathan Pennell: 3 Questions That Matter for the Next Multiple Myeloma Treatment
Nathan Pennell, Senior Vice President, Head of Global Medical Oncology at Bristol Myers Squibb, shared a post on LinkedIn:
“Years in the clinic have taught me to ask three questions about every new treatment:
- How well does it work?
- What does the safety profile look like?
- How can we work to make sure it reaches the patients who need it?
The Phase 3 EXCALIBER-RRMM results presented at IMS26 today give me real reason for optimism on all three counts. I’m genuinely excited by what they could mean for patients with relapsed/refractory multiple myeloma.
Having spent years working toward a future where more patients actually receive the medicines they need, I couldn’t be prouder to be part of a team accelerating the journey from scientific discovery to patient impact.
Thank you to the colleagues, investigators and patients advancing this critical research.”
Stay updated with Hemostasis Today.
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics